---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024338"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2025-08-15T23:59:59+00:00"
generated_at: "2026-05-17T12:21:08.551648+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M

## Summary
- Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.
- Net loss from continuing operations $(3.2)M vs $(2.2)M in Q2 2024.
- Adjusted EBITDA $(587,230) vs $(509,623) in prior year period.
- Completed divestiture of majority stake in NAYA Therapeutics; retains minority position.
- Launched telehealth and PRP therapy at Wisconsin clinic; received patent allowance for INVOcell device through 2040.

## SEC filing metadata
- accession: 0001641172-25-024338
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2025-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000164117225024338/0001641172-25-024338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000164117225024338/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024338
- JSON: https://secwatch.observer/filing/0001641172-25-024338.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024338.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.